ABSTRACT
Background The pathogenesis of amyotrophic lateral sclerosis (ALS) involves both genetic and environmental factors. This study investigates associations between metal measures in plasma and urine, ALS risk and survival, and exposure sources.
Methods Participants with and without ALS from Michigan provided plasma and urine samples for metal measurement via inductively coupled plasma mass spectrometry. Odds and hazard ratios for each metal were computed using risk and survival models. Environmental risk scores (ERS) were created to evaluate the association between exposure mixtures and ALS risk and survival and exposure source. ALS (ALS-PGS) and metal (metal-PGS) polygenic risk scores were constructed from an independent genome-wide association study and relevant literature-selected SNPs.
Results Plasma and urine samples from 454 ALS and 294 control participants were analyzed. Elevated levels of individual metals, including copper, selenium, and zinc, significantly associated with ALS risk and survival. ERS representing metal mixtures strongly associated with ALS risk (plasma, OR=2.95, CI=2.38-3.62, p<0.001; urine, OR=3.10, CI=2.43-3.97, p<0.001) and poorer ALS survival (plasma, HR=1.42, CI=1.24-1.63, p<0.001; urine, HR=1.52, CI=1.31-1.76, p<0.001). Addition of the ALS-PGS or metal-PGS did not alter the significance of metals with ALS risk and survival. Occupations with high potential of metal exposure associated with elevated ERS. Additionally, occupational and non-occupational metal exposures associated with measured plasma and urine metals.
Conclusion Metals in plasma and urine associated with increased ALS risk and reduced survival, independent of genetic risk, and correlated with occupational and non-occupational metal exposures. These data underscore the significance of metal exposure in ALS risk and progression.
Competing Interest Statement
DGJ: None. JD: None. EJK: None. ST: None. LZ: None. KMB: None. BM: None. SAB: None. ELF: Listed as inventors on a patent, Issue number US10660895, held by University of Michigan titled Methods for Treating Amyotrophic Lateral Sclerosis that targets immune pathways for use in ALS therapeutics. SAG: Listed as inventors on a patent, Issue number US10660895, held by University of Michigan titled Methods for Treating Amyotrophic Lateral Sclerosis that targets immune pathways for use in ALS therapeutics. Scientific consulting for Evidera.
Funding Statement
Funding was provided by the National Institute of Neurological Disorders and Stroke (NINDS) (R01NS127188); National Institute of Environmental Health Sciences (NIEHS) (K23ES027221, R01ES030049); Centers for Disease Control and Prevention (R01TS000344); ALS Association (20-IIA-532, 20-PP-661); NeuroNetwork for Emerging Therapies; Peter R. Clark Fund for ALS Research; Robert and Katherine Jacobs Environmental Health Initiative; Richard Stravitz Foundation; Coleman Therapeutic Discovery Fund; Scott L. Pranger ALS Clinic Fund; the Dr. Randall W. Whitcomb Fund for ALS Genetics; University of Michigan. Metals analysis was carried out at the Dartmouth Trace Element Core Facility, which is supported by Dartmouth Cancer Center with NCI Cancer Center Support Grant 5P30 CA023108.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the University of Michigan gave ethical approval for this work (HUM28826).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Dae Gyu Jang dajang{at}med.umich.edu, John Dou johndou{at}umich.edu, Emily Koubek ekoubek{at}med.umich.edu, Samuel Teener steener{at}med.umich.edu, Lili Zhao zhaolili{at}umich.edu, Kelly Bakulski bakulski{at}umich.edu, Bhramar Mukherjee bhramar{at}umich.edu, Stuart Batterman stuartb{at}umich.edu, Eva L. Feldman efeldman{at}umich.edu, Stephen A Goutman, sgoutman{at}med.umich.edu
Data Availability
Sharing of non-identifiable data will be considered at the reasonable request of a qualified investigator.
